Skip to content

Amgen AMGN Finished goods

Finished goods at other companies

Pfizer logo
PfizerPFE
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$8.6B+5.8%
Gross profit$5.9B+13.4%
Operating income$2.7B+126%
Net income$1.8B+5.1%
EPS (diluted)$3.34+4.4%

Balance sheet

See full
Cash & equivalents$559.0M+10.0%
Total debt$57.3B-0.1%
Total equity$9.2B+48.1%
Total assets$92.5B+3.5%

Cash flow

See full
Operating cash flow$2.2B+57.4%
CapEx$712.0M+73.2%
Free cash flow$1.5B+50.7%

Valuation

See full
Market cap$195.44B+34.6%
Enterprise value$252.2B+25.7%
P/E25.1×+3.1×
P/S5.3×+1.1×

Profitability

See full
Gross margin68.3%+5.3pp
Operating margin28.4%+6.6pp
Net margin21%+3.6pp
FCF margin23.1%-8.9pp

Returns & leverage

See full
Return on equity101.3%-4.4pp
Debt / equity6.2×-3.0×
Current ratio1.3×+0.1×

Where this comes from

Reported directly by Amgen in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Amgen’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amgen's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amgen's finished goods?
Amgen (AMGN) reported finished goods of $1.71B in Q1 2026.
How has Amgen's finished goods changed year-over-year?
Amgen's finished goods decreased by 11.2% year-over-year, from $1.93B to $1.71B.
What is the long-term trend for Amgen's finished goods?
Over 5 years (2020 to 2025), Amgen's finished goods has grown at a 14.2% compound annual growth rate (CAGR), from $970M to $1.89B.